Zelgen Biopharmaceutical's Phase II Trial of Gecaxitinib Hydrochloride Tablets Shows Positive Results
Zelgen Biopharmaceutical's Phase II Trial of Gecaxitinib Hydrochloride Tablets Shows Positive Results
泽珍生物制药的Gecaxitinib Hydrochloride片的II期试验呈现出积极结果
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册